Synlogic (STU:MIN) ROCE %: -36.70% (As of Mar. 2026)

What is Synlogic ROCE %?

Synlogic STU:MIN 28 ROCE % is -36.70% as of Mar. 2026. GuruFocus rates STU:MIN with a GF Score™ of 28/100 and a GF Value™ of €0.15. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synlogic's annualized ROCE % for the quarter that ended in Mar. 2026 was -36.70%.

Synlogic (STU:MIN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synlogic ROCE % Related Terms

Synlogic ROCE % Historical Data

* Premium members only.

The historical data trend for Synlogic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synlogic ROCE % Chart

Synlogic Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-41.69

-52.27

-83.39

-56.13

-27.04

Synlogic Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-26.15	-23.66	-28.57	-38.33	-36.70

28GF Score

Synlogic Inc STU:MIN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Synlogic ROCE % Calculation

Synlogic's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-3.016	/	( ( (18.934 - 6.757)	+	(13.192 - 3.061) )	/ 2 )
	=	-3.016	/	( (12.177	+	10.131)	/ 2 )
	=	-3.016	/	11.154
	=	-27.04 %

Synlogic's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-3.852	/	( ( (13.192 - 3.061)	+	(12.639 - 1.779) )	/ 2 )
	=	-3.852	/	( ( 10.131	+	10.86 )	/ 2 )
	=	-3.852	/	10.4955
	=	-36.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -36.70% mean?

Synlogic (STU:MIN) has a ROCE % of -36.70% as of Mar. 2026.

Is Synlogic's ROCE % too high?

Synlogic's current ROCE % is -36.70%. Overall, Synlogic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Synlogic's ROCE % compare to CNSP and ELAB?

Synlogic's ROCE % of -36.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Synlogic's current ROCE % is -36.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Synlogic stock overvalued right now?

Synlogic (STU:MIN) has a current ROCE % of -36.70%. The stock's GF Value™ is €0.15, compared to a current price of €3.63 — trading 2320% above its estimated fair value. The current ROCE % is -36.70%. Synlogic's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Synlogic (STU:MIN), the current ROCE % is -36.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synlogic (STU:MIN) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of €3.63 is trading 2320% above its estimated GF Value™ of €0.15.

Key valuation signals for STU:MIN:

ROCE %: -36.70%
GF Value™: €0.15 vs. price of €3.63 (2320% above fair value)
GF Score™: 28/100 with 1 warning sign

No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Industry Healthcare Biotechnology

Comparable Companies CNSP ELAB GNPX BCLI APM CELZ ENVB ACXP LIMN XBIO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SYBX:USA 0A8U:UK

Address PO Box 30, Winchester, MA, USA, 01890

Website https://www.synlogictx.com

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.

28GF Score

Get the complete analysis for STU:MIN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.63

Price

€0.15

GF Value

View STU:MIN Analysis

See ROCE % data for all stocks →